ETX-018810

ETX-018810 is a small molecule, non-opioid prodrug of palmitoylethanolamide (PEA), an endogenous bioactive lipid. It was developed as a novel treatment for chronic pain syndromes, particularly neuropathic pain conditions such as diabetic peripheral neuropathic pain and lumbosacral radicular pain. The drug acts through multiple mechanisms, including agonism at cannabinoid receptors, modulation of G-protein-coupled receptor 55 (GPR55), and activation of peroxisome proliferator-activated receptor alpha (PPARα). Additionally, it has been described as a MAPK inhibitor. Clinical trials reached Phase 2 for indications including radiculopathy and neuropathic pain but development has since been discontinued[1][2][3][5][7].

Other names

ETX 810ETX810ETX-810